SCHEMBL29699530

SCHEMBL29699530

Clc1ccc(Cl)c(Nc2c[nH]nn2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.42
C1R P00736 1/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
POLB P06746 1/20 0.38
MAP2K1 Q02750 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CXCL8 P10145 1/20 0.36
MCL1 Q07820 1/20 0.36
PDGFRB P09619 1/20 0.36
IDO1 P14902 1/20 0.36
CDK4 P11802 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15831500 0.81 TNIK (0.41) POLBALDH1A1
SCHEMBL4163888 0.79 KMT2A (0.45) C1RMEN1KMT2AALDH1A1CDK2
SCHEMBL29699470 0.75 POLA1 (0.47) RAPGEF4HDAC3HDAC1HDAC2HDAC6
SCHEMBL23457614 0.74 CYP1A2 (0.41) CYP1A2MEN1KMT2AALDH1A1
SCHEMBL29699460 0.74 CYP1A2 (0.41) CYP1A2MEN1KMT2AALDH1A1
SCHEMBL29699617 0.74 SCN9A (0.38) CYP1A2CYP3A4CYP2C19IDO1EGFR
SCHEMBL23457623 0.74 SCN9A (0.38) CYP1A2CYP3A4CYP2C19IDO1EGFR
SCHEMBL17281222 0.73 IDO1 (0.37) ALDH1A1IDO1EGFR
SCHEMBL23457551 0.72 MAPT (0.36) HDAC1HDAC2POLBALDH1A1PDGFRB
SCHEMBL29699548 0.72 MAPT (0.36) HDAC1HDAC2POLBALDH1A1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT RAPGEF4 3822/4885C1R 3193/4885CYP2C9 486/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT RAPGEF4 3950/4885C1R 3336/4885CYP2C9 523/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT RAPGEF4 3822/4885C1R 3193/4885CYP2C9 486/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT RAPGEF4 3822/4885C1R 3193/4885CYP2C9 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.